EU Revises Liposomal Drug Naming Advice
The Focus Is On Drugs At High Risk Of Medication Errors
Executive Summary
Marketing authorization holders of liposomal drug delivery systems will have to consider elements such as route of administration, medication error reporting or long-established use to assess whether their medicines are prone to medication errors.